



CONFINDUSTRIA ROMAGNA

INNOVAZIONE

Comunicazione INN/2020 del 10/04/2020

a cura di Barbara Calzi

Covid-19 : call aperte a livello europeo

Alleghiamo la Nota di CONFINDUSTRIA che elencano e illustrano brevemente le call aperte in Europa per progetti inerenti il Covid-19.

Per ulteriori informazioni, le Aziende interessate possono rivolgersi al Servizio Innovazione (Ref. Barbara Calzi bcalzi@confindustriaromagna.it - 0543727724).

Allegato:

- Covid-19 Call e iniziative UE in corso - Aprile 2020

COVID 19

Call e iniziative UE in corso

Aprile 2020

Sommario

HORIZON 2020 - Innovative Medicines Initiative (IMI) – Public Private Partnership	2
HORIZON 2020 PRIZE.....	3
EIT HEALTH.....	3
EUvsVIRUS HACKATHON - 24, 25, 26 APRIL 2020	4
AI-ROBOTICS vs COVID-19 initiative of the European AI Alliance	4
EUROPEAN INNOVATION COUNCIL: EIC SOLUTIONS TO FIGHT COVID19.....	4
EUROPEAN INVESTMENT BANK: INNOVFIN INFECTIOUS DISEASES	4

HORIZON 2020 - Innovative Medicines Initiative (IMI) – Public Private Partnership

[IMI2 - Call 20 Call ID: H2020-JTI-IMI2-2020-20-two-stage](#)

Action Type: RIA – Research and Innovation Actions

Update 08/04/2020: The deadline for submitting short proposals has been extended to 12 May 2020.

Indicative budget

From EFPIA companies and IMI2 Associated Partners: EUR 140 209 500

From the IMI2 JU: EUR 133 009 000

Key dates and deadlines

Draft topic texts published: 15 October 2019

Publication date: 21 January 2020

Stage 1 submission start date: 21 January 2020

Stage 1 submission deadline: ~~21 April 2020~~ 12 May 2020

Stage 2 submission deadline: ~~5 November 2020~~ 19 November 2020

Topics

1. [Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in psoriatic arthritis](#)
2. [Innovations to accelerate vaccine development and manufacture](#)
3. [Academia and industry united innovation and treatment for tuberculosis \(UNITE4TB\)](#)
This topic is part of the IMI [AMR Accelerator Programme](#). Applicants should also read the [Questions and Answers](#) on the programme (document last updated November 2019).
4. [Tumour plasticity](#)
5. [Proton versus photon therapy for oesophageal cancer – a trimodality strategy](#)
6. [Handling of protein drug products and stability concerns](#)

For full details of the topics, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Participant Portal) or read the [IMI2 - Call 20 Text](#).

HORIZON 2020 PRIZE

Early Warning for Epidemics

Deadline: 1st September 2020

Budget: 5 million

This prize aims to **develop an early-warning system to help prevent disease outbreaks** and reduce the impact should they occur.

The challenge is to develop a **scalable, reliable, and cost-effective early-warning system prototype to forecast and monitor vector-borne diseases** in order to contribute to the prevention of outbreaks, mitigating their impact on local, regional and global scales, and providing support to existing elimination efforts.

According to the World Health Organisation (WHO), vector-borne diseases such as malaria, Zika, dengue or yellow fever cause more than 1 million deaths globally each year.

Vectors are living organisms that can transmit infectious diseases between humans or from animals to humans. Vector-borne diseases are a global threat to public health and can have far-reaching economic and social impacts.

EIT HEALTH

Headstart Funding for COVID-19 Solutions

Deadline: 14 April 2020

[Headstart](#) provides companies that are chosen for the programme up to **€50,000** to support the development of innovative healthcare products and services. This year, Headstart is supplemented by a special programme focused on COVID-19 solutions.

COVID-19 Solutions

Calling **digital health start-ups** with valuable COVID-19 solutions. Through Headstart, EIT Health will award up to €50,000 to companies with the potential to enable the community and health systems to fill in the gap until COVID-19 vaccines are ready. We are looking for products or services with [technology readiness level eight](#). We are accepting applications for this call until 14 April 2020. For more details, please refer to the [Headstart for COVID-19 Guide](#).

Applications must be filed through the [EIT Health Optimy Registration platform](#).

EUvsVIRUS HACKATHON - 24, 25, 26 APRIL 2020

EUvsVirus Hackathon aims to develop innovative solutions and overcome coronavirus-related challenges

To complement hackathons taking place at global and member state level, **the European Commission - in close collaboration with EU member states – will host a pan-European hackathon to connect civil society, innovators, partners and buyers across Europe to develop innovative solutions to coronavirus.**

The #EUvsVirus Hackathon will take place **on 24, 25 and 26 April** and address approximately 20 imminent coronavirus challenges (e.g. fast production of equipment, scaling up production capabilities, knowledge and solutions transfer from one country to another), to be quickly developed and deployed across the EU Single Market.

AI-ROBOTICS vs COVID-19 initiative of the European AI Alliance

The European Commission launches an initiative to collect ideas about deployable **Artificial Intelligence (AI) and Robotics solutions** as well as information on other initiatives that could help face the ongoing COVID-19 crisis.

EUROPEAN INNOVATION COUNCIL: EIC SOLUTIONS TO FIGHT COVID19

The EIC Group spreading innovation to tackle Coronavirus. The EIC is already supporting a number of SMEs and researchers with Coronavirus relevant innovations, awarded funding in previous rounds. With this in mind, the European Innovation Council Community is now creating an online space to bring together these key players, including leading researchers and SMEs pursuing 2019-nCoV critical animal health and public health research and the development of vaccines, therapeutics and diagnostics, among other innovations.

EUROPEAN INVESTMENT BANK: INNOVFIN INFECTIOUS DISEASES

The **InnovFin Infectious Diseases Finance Facility (IDFF)** provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases. Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement. The product is being made available directly through the European Investment Bank. [PDF in italiano](#)